Euglycemic DKA (euDKA) is a serious side effect associated with SGLT2 inhibitors. We present a case euDKA in a patient on an SGLT-2 inhibitor likely precipitated by COVID-19 infection. We suspect that COVID-19 led to euDKA. We pose the question of whether these medications should be discontinued proactively.